RxDoctor Payments Data

Grace Esmalla, APRN

Psychiatric/Mental Health · Frankfort, ILNPI 1225762057

Payments from drug & device makers

$4,252in general payments, 2019–2025

Across 149 payments — averaging $28.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$1K
  • Johnson & Johnson$497
  • Neurocrine Biosciences, Inc.$429
  • Alkermes, Inc.$336
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$289
  • AbbVie$250
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$4,252100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,252 in reported general payments places this provider in the 90th percentile of 922 psychiatric/mental health providers in Illinois.

See all psychiatric/mental health providers in Illinois

Medicare billing

Part B allowed, 2024
$29,059
Medicare patients
33
Services billed
344

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole24$57,369
Aripiprazole37$16,254
Fluvoxamine Maleate100$8,527
Divalproex Sodium ErDivalproex Sodium87$5,911
Fluvoxamine Maleate ErFluvoxamine Maleate15$2,967
Divalproex Sodium24$2,842
Olanzapine43$2,205
Benztropine Mesylate95$1,562
Fluoxetine Hcl110$1,530
Ziprasidone Hcl14$1,390
Clonazepam103$1,349
Lorazepam86$890
Buspirone Hcl11$836
Risperidone64$788
Quetiapine Fumarate11$665

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$1,077$57,36924 claims
Lilly USA, LLCOlanzapine$17$2,20543 claims
Almatica Pharma LLCSertraline Hcl$53$19116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 922 psychiatric/mental health providers in Illinois.

Other psychiatric/mental health in Frankfort

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →